Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May 21;20(19):5730-6.
doi: 10.3748/wjg.v20.i19.5730.

Optimization therapy for the treatment of chronic hepatitis B

En-Qiang Chen  1 , Hong Tang  1
Affiliations
Review

Optimization therapy for the treatment of chronic hepatitis B

En-Qiang Chen et al. World J Gastroenterol. .

Abstract

Chronic hepatitis B (CHB) is currently medically managed with either interferon-alpha or one of the five nucleos(t)ide analogs. However, there are still a large number of CHB patients whose response to the above therapies remains less than satisfactory, and their incomplete or non-response to antiviral therapies has plagued clinicians worldwide. In recent years, a newly proposed optimization therapy has provided us with a new approach to solve this problem. The key points in this optimization therapy are to initiate antiviral therapy with an appropriate agent at the correct time point, and to adjust treatments in patients with poor early responses by adding a second agent or switching to another more potent agent. In this review, we summarize recent developments in optimization therapy for the treatment of CHB, and provide an outlook for future research in this field.

Keywords: Chronic hepatitis B; Interferon; Nucleos(t)ide analog; Optimization therapy; Suboptimal response.

PubMed Disclaimer

References

    1. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486–1500. - PubMed
    1. Jia J. A different look at the management of chronic hepatitis B in a resource-constrained country. J Viral Hepat. 2013;20 Suppl 1:1. - PubMed
    1. McMahon BJ, Bulkow L, Simons B, Zhang Y, Negus S, Homan C, Spradling P, Teshale E, Lau D, Snowball M, et al. Relationship Between Level of Hepatitis B Virus DNA and Liver Disease: A Population-based Study of Hepatitis B e Antigen-Negative Persons With Hepatitis B. Clin Gastroenterol Hepatol. 2014;12:701–706.e3. - PMC - PubMed
    1. Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H. Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. World J Gastroenterol. 2012;18:7149–7157. - PMC - PubMed
    1. Ferreira PR, Tenore Sde B. Response predictors to treatment with pegylated interferon in chronic hepatitis B. Braz J Infect Dis. 2010;14:519–525. - PubMed

Publication types

LinkOut - more resources